Acumen Pharmaceuticals (NASDAQ: ABOS)
1 known investors
Acumen is a biopharmaceutical company developing targeted therapies for Alzheimer's disease. It focuses on advancing treatment outcomes in the neurodegenerative disease field.
Investors Β· 1
Non-dilutive funding Β· 4 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $222.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $176.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $183.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $145.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Acumen Pharmaceuticals (NASDAQ: ABOS) do?
- Acumen is a biopharmaceutical company developing targeted therapies for Alzheimer's disease. It focuses on advancing treatment outcomes in the neurodegenerative disease field.
- Who are Acumen Pharmaceuticals (NASDAQ: ABOS)'s investors?
- Acumen Pharmaceuticals (NASDAQ: ABOS)'s investors include K2 HealthVentures.